Palomid 529

DRUG2 trials

Sponsors

Paloma Pharmaceuticals, Inc., National Eye Institute (NEI)

Conditions

Age-Related Macular Degeneration

Phase 1

Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration

CompletedNCT01033721

Paloma Pharmaceuticals, Inc.Age-Related Macular Degeneration

Start: 2010-06-30End: 2011-12-31Updated: 2012-09-24

Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration

CompletedNCT01271270

National Eye Institute (NEI)Age-Related Macular Degeneration

Start: 2010-12-20End: 2012-09-20Updated: 2018-07-05